PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Cash & equivalents declining -3.43% while AXSM's grows 77.32%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of AXSM's 77.32%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Above 1.5x AXSM's 13.65%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-3.05%
Below half of AXSM's 70.70%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
Below half AXSM's 907.17%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AXSM's -1.68%. Michael Burry warns of potential hidden liabilities or intangible bloat.
0.98%
Below half of AXSM's 8.52%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of AXSM's 57.16%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
1.25-1.5x AXSM's -72.24%. Martin Whitman sees a potentially higher near-term liability load.
16.37%
1.1-1.25x AXSM's 14.23%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of AXSM's 23.28%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Less than half of AXSM's 20.00%. David Dodd sees far fewer liability expansions relative to competitor.
3.85%
Less than half of AXSM's 25.00%. David Dodd sees fewer share issuances vs. competitor.
-5.06%
Below half AXSM's -11.06%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
Below half AXSM's 149.35%. Michael Burry sees potential underperformance in building shareholder capital.
-2.92%
Below half AXSM's 57.16%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Less than half of AXSM's 25.04%. David Dodd sees less overall debt expansion vs. competitor.
3.39%
Less than half of AXSM's -155.49%. David Dodd sees better deleveraging or stronger cash buildup than competitor.